MX2024006954A - Anticuerpos anti calreticulina (calr) mutante y usos de estos. - Google Patents
Anticuerpos anti calreticulina (calr) mutante y usos de estos.Info
- Publication number
- MX2024006954A MX2024006954A MX2024006954A MX2024006954A MX2024006954A MX 2024006954 A MX2024006954 A MX 2024006954A MX 2024006954 A MX2024006954 A MX 2024006954A MX 2024006954 A MX2024006954 A MX 2024006954A MX 2024006954 A MX2024006954 A MX 2024006954A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- calr
- mutant calreticulin
- mutcalr
- calreticulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287394P | 2021-12-08 | 2021-12-08 | |
| US202163288479P | 2021-12-10 | 2021-12-10 | |
| US202263421052P | 2022-10-31 | 2022-10-31 | |
| PCT/US2022/081076 WO2023107994A1 (en) | 2021-12-08 | 2022-12-07 | Anti-mutant calreticulin (calr) antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006954A true MX2024006954A (es) | 2024-06-21 |
Family
ID=84943209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006954A MX2024006954A (es) | 2021-12-08 | 2022-12-07 | Anticuerpos anti calreticulina (calr) mutante y usos de estos. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230272055A1 (https=) |
| EP (1) | EP4444343A1 (https=) |
| JP (1) | JP2025500796A (https=) |
| KR (1) | KR20240127992A (https=) |
| AU (1) | AU2022407445A1 (https=) |
| CA (1) | CA3241889A1 (https=) |
| CL (2) | CL2024001654A1 (https=) |
| CO (1) | CO2024009042A2 (https=) |
| CR (1) | CR20240277A (https=) |
| DO (1) | DOP2024000110A (https=) |
| GE (1) | GEAP202416555A (https=) |
| IL (1) | IL313366A (https=) |
| JO (1) | JOP20240122A1 (https=) |
| MX (1) | MX2024006954A (https=) |
| PE (1) | PE20241998A1 (https=) |
| TW (1) | TW202330623A (https=) |
| UY (1) | UY40062A (https=) |
| WO (1) | WO2023107994A1 (https=) |
| ZA (1) | ZA202404295B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117467004B (zh) * | 2023-10-09 | 2024-06-21 | 武汉爱博泰克生物科技有限公司 | 抗人钙网膜蛋白的兔单克隆抗体及其应用 |
| WO2025096716A1 (en) * | 2023-11-01 | 2025-05-08 | Incyte Corporation | Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof |
| WO2026013015A1 (en) * | 2024-07-09 | 2026-01-15 | Merus N.V. | Multispecific binding moieties comprising calr and cd3 binding domains |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Ｐｉ3ｋ 저해물질로서의 피리미디논 |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| TWI646099B (zh) | 2012-11-01 | 2019-01-01 | 英塞特控股公司 | 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物 |
| WO2016087514A1 (en) | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| SG11202108494YA (en) * | 2019-02-28 | 2021-09-29 | Juntendo Educational Found | Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm |
-
2022
- 2022-12-07 GE GEAP202416555A patent/GEAP202416555A/en unknown
- 2022-12-07 MX MX2024006954A patent/MX2024006954A/es unknown
- 2022-12-07 KR KR1020247022555A patent/KR20240127992A/ko active Pending
- 2022-12-07 US US18/062,924 patent/US20230272055A1/en active Pending
- 2022-12-07 AU AU2022407445A patent/AU2022407445A1/en active Pending
- 2022-12-07 JP JP2024534342A patent/JP2025500796A/ja active Pending
- 2022-12-07 CR CR20240277A patent/CR20240277A/es unknown
- 2022-12-07 CA CA3241889A patent/CA3241889A1/en active Pending
- 2022-12-07 EP EP22843595.4A patent/EP4444343A1/en active Pending
- 2022-12-07 TW TW111146965A patent/TW202330623A/zh unknown
- 2022-12-07 IL IL313366A patent/IL313366A/en unknown
- 2022-12-07 UY UY0001040062A patent/UY40062A/es unknown
- 2022-12-07 WO PCT/US2022/081076 patent/WO2023107994A1/en not_active Ceased
- 2022-12-07 PE PE2024001321A patent/PE20241998A1/es unknown
-
2024
- 2024-05-29 JO JOJO/P/2024/0122A patent/JOP20240122A1/ar unknown
- 2024-05-31 ZA ZA2024/04295A patent/ZA202404295B/en unknown
- 2024-06-03 CL CL2024001654A patent/CL2024001654A1/es unknown
- 2024-06-06 DO DO2024000110A patent/DOP2024000110A/es unknown
- 2024-07-08 CO CONC2024/0009042A patent/CO2024009042A2/es unknown
-
2025
- 2025-01-24 CL CL2025000229A patent/CL2025000229A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2024000110A (es) | 2024-09-30 |
| PE20241998A1 (es) | 2024-09-27 |
| GEAP202416555A (en) | 2024-10-28 |
| ZA202404295B (en) | 2025-02-26 |
| IL313366A (en) | 2024-08-01 |
| TW202330623A (zh) | 2023-08-01 |
| JP2025500796A (ja) | 2025-01-15 |
| KR20240127992A (ko) | 2024-08-23 |
| UY40062A (es) | 2023-06-30 |
| CO2024009042A2 (es) | 2024-08-08 |
| CL2025000229A1 (es) | 2025-06-06 |
| EP4444343A1 (en) | 2024-10-16 |
| CR20240277A (es) | 2024-08-07 |
| AU2022407445A1 (en) | 2024-06-13 |
| US20230272055A1 (en) | 2023-08-31 |
| CA3241889A1 (en) | 2023-06-15 |
| JOP20240122A1 (ar) | 2024-05-29 |
| WO2023107994A1 (en) | 2023-06-15 |
| CL2024001654A1 (es) | 2024-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006954A (es) | Anticuerpos anti calreticulina (calr) mutante y usos de estos. | |
| CL2024002235A1 (es) | Anticuerpo anti-cd73 humano; método de producción; composición farmacéutica; y su uso. | |
| PE20220231A1 (es) | Proteinas de fusion flt3l-fc y metodos de uso | |
| CL2021001686A1 (es) | Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378) | |
| CO2020016586A2 (es) | Diversos dominios de enlace de antígenos, nuevas plataformas y otras mejoras para terapia celular | |
| EA201992001A1 (ru) | Композиции и способы повышения экспрессии генов | |
| UY37758A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
| CL2023001493A1 (es) | Anticuerpos anti-ly6g6d y métodos de uso. | |
| BR112019012343A2 (pt) | anticorpos il-11ra | |
| MX2020010235A (es) | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. | |
| MX2020004541A (es) | Edicion de genes de celulas primarias. | |
| CR20220186A (es) | ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225) | |
| EP4442706A3 (en) | Canine antibody libraries | |
| CO2023015915A2 (es) | Anticuerpos anti-ccr8 | |
| MX2022005815A (es) | Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70. | |
| MX2021015301A (es) | Métodos de cultivo celular y composiciones para la producción de anticuerpos. | |
| AR109635A1 (es) | Mezcla aditiva | |
| MX2023002373A (es) | Receptores de antígenos quiméricos bcma. | |
| CO2024000024A2 (es) | Moléculas de unión a gpc3 | |
| CL2019000682A1 (es) | Identificación y aislamiento del progenitor ótico humano. | |
| MX2021012649A (es) | Medio de cultivo celular para celulas eucarioticas. | |
| AR127891A1 (es) | Anticuerpos anti-calreticulina (calr) mutante y usos de estos | |
| MX2015017714A (es) | Selecciones fenotipicas, descubrimiento del antigeno objetivo y uso de los mismos para la identificacion de epitopes objetivo especificos de celulas objetivo. | |
| AU2016204734B2 (en) | Method for generating high-titer Hepatitis E virus stocks and titration assay for Hepatitis E virus | |
| AR126364A2 (es) | Anticuerpos anti-cd3 y métodos de uso |